Zimmer Biomet Holdings (ZBH, Financials) has entered into an agreement to acquire Paragon 28 (FNA, Financials) for approximately $1.2 billion, including an equity value of $1.1 billion.
Worth around $5 billion, the agreement broadens Zimmer Biomet's portfolio into the foot and ankle market.
Depending on income targets, Paragon 28 shareholders will get $13 per share in cash under the conditions along with an extra non-tradeable contingent value right (CVR) of up to $1 per share. Should net sales in Zimmer Biomet's 2026 fiscal year surpass $346 million, the CVR scales up to $361 million.
Approved by both businesses' boards, the deal is scheduled to conclude in the first half of 2025 depending on shareholder approval and regulatory clearances.
Established in 2010, Paragon 28 focuses on foot and ankle orthopedic devices and provides surgical treatments including joint replacement, deformity correction, and fracture and trauma repair. The purchase will improve Zimmer Biomet's standing in a high-growth market and support its ambulatory surgical center operations.
Though it estimates a temporary dilution of around 3% to adjusted profits per share in 2025 and roughly 1% in 2026, Zimmer Biomet expects the purchase to immediately help to contribute to sales growth. The purchase is expected to be accretive to income in 24 months.
Maintaining its capital allocation goals, Zimmer Biomet will fund the deal using debt and current cash. The fourth-quarter results call of the corporation on February 6, 2025 will go into further financial specifics.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。